The Pharmaceutical Benefits Advisory Committee is set to recommend the addition of RU486 to the Pharmaceutical Benefits Scheme today, and the medical abortion drug is likely to get the go-ahead from Health Minister Tanya Plibersek.
But listing on the PBS isn't automatic -- the net cost implications to taxpayers of listing additional drugs are subject to vetting by the Department of Finance, and major new additions need cabinet approval.
Join the conversation
The Crikey comment section is members-only content. Please login or sign up for a FREE trial to engage in the commentary.